SYRE Q4 2023 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$46M

Net Income

-$63M

EPS (Diluted)

$-2.91

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$342M

Total Liabilities

$158M

Stockholders' Equity

$184M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$168,000	-100.0%
Gross Profit	$0	-$322,000	+100.0%
Operating Income	-$46M	-$19M	-139.6%
Net Income	-$63M	-$19M	-235.7%